Trial Profile
Long-term tolerability of a new epoprostenol formulation in patients with pulmonary arterial hypertension
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 30 Apr 2014
Price :
$35
*
At a glance
- Drugs Epoprostenol (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Acronyms EPITOME-2
- 30 Apr 2014 New trial record